Advertisement

Topics

Oxford Immunotec nets $39mm through public offering

15:40 EDT 18 Aug 2017 | Elsevier Business Intelligence

Oxford Immunotec Global PLC (developing diagnostics for immune-regulated conditions including tuberculosis, Lyme, and Babesia...

Original Article: Oxford Immunotec nets $39mm through public offering

NEXT ARTICLE

More From BioPortfolio on "Oxford Immunotec nets $39mm through public offering"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Infectious-diseases
Antiretroviral Therapy Clostridium Difficile Ebola HIV & AIDS Infectious Diseases Influenza Malaria Measles Sepsis Swine Flu Tropical Medicine Tuberculosis Infectious diseases are caused by pathogenic...